Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 6Phase 1/2 2Phase NA 1

Status

Completed 1

Sponsor Class

NETWORK 2OTHER_GOV 1OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 38Prostatic Neoplasms 18Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lung Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Neoplasms 14Leukemia 13Rectal Neoplasms 12Uterine Cervical Neoplasms 10Unspecified Adult Solid Tumor, Protocol Specific 10Colorectal Neoplasms 10Colonic Neoplasms 10Sarcoma 9Leukemia, Myeloid, Acute 8Central Nervous System Neoplasms 8Brain Neoplasms 8Pain 7Ovarian Neoplasms 7Neuroblastoma 7Myelodysplastic Syndromes 7Leukemia, Lymphocytic, Chronic, B-Cell 7Head and Neck Neoplasms 7Small Cell Lung Carcinoma 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Carcinoma, Ovarian Epithelial 6Burkitt Lymphoma 6Testicular Neoplasms 5Sezary Syndrome 5

Interventions

Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × NIH × Esthesioneuroblastoma, Olfactory × Clear all
NCT00068497 2013-01-14

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase NA Completed
40 enrolled
CNSEndocrineHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Parathyroid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡